Aurisco Pharmaceutical Co Ltd (605116) — Cash Flow Quality Index
Aurisco Pharmaceutical Co Ltd (605116) has a Cash Flow Quality Index of 0.94x as of December 2024. Operating cash flow of CN¥332.41 Million is below net income of CN¥354.79 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Aurisco Pharmaceutical Co Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Aurisco Pharmaceutical Co Ltd Cash Flow Quality Index (2017–2024)
Historical Cash Flow Quality Index for Aurisco Pharmaceutical Co Ltd across 8 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 605116 cash flow conversion.
Annual Cash Flow Quality Index for Aurisco Pharmaceutical Co Ltd (2017–2024)
Year-by-year earnings quality comparison for Aurisco Pharmaceutical Co Ltd.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.94x | CN¥332.41 Million | CN¥354.79 Million | ▼ -29.7% |
| 2023 | 1.33x | CN¥385.61 Million | CN¥289.42 Million | ▲ +66.7% |
| 2022 | 0.80x | CN¥166.41 Million | CN¥208.21 Million | ▼ -33.3% |
| 2021 | 1.20x | CN¥201.57 Million | CN¥168.28 Million | ▼ -12.2% |
| 2020 | 1.36x | CN¥214.48 Million | CN¥157.23 Million | ▲ +41.1% |
| 2019 | 0.97x | CN¥179.90 Million | CN¥186.13 Million | ▲ +20.5% |
| 2018 | 0.80x | CN¥109.77 Million | CN¥136.83 Million | ▼ -69.6% |
| 2017 | 2.64x | CN¥117.91 Million | CN¥44.72 Million | — |